Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | January 20, 2026 | January 21, 2026 |
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Development Officer | September 29, 2026 | October 02, 2026 |
| Zai Lab LtdZLAB · Entity 4271 | Head of Global Dev., Oncology | June 25, 2022 | June 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2036-01-19 | Direct | 10,100 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 10,100 · Balance 10,100 F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
Revolution Medicines, Inc.
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,868 |
Reported balance
After 2026-09-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-29 · Exercise / conversion · Acquired 6,000 · Balance 58,868 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 56,668 |
Reported balance
After 2026-09-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-29 · Sale · Disposed 2,200 · Balance 56,668 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2: The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 55,059 |
Reported balance
After 2026-09-29 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-29 · Sale · Disposed 1,609 · Balance 55,059 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3: The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 54,059 |
Reported balance
After 2026-09-29 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-29 · Sale · Disposed 1,000 · Balance 54,059 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F4: The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 52,860 |
Reported balance
After 2026-09-29 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-29 · Sale · Disposed 1,199 · Balance 52,860 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F5: The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 52,559 |
Reported balance
After 2026-09-29 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-29 · Sale · Disposed 301 · Balance 52,559 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F6: The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7: Includes 52,350 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.84 · Expires 2035-11-01 | Direct | 161,300 |
Reported balance
After 2026-09-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-29 · Exercise / conversion · Disposed 6,000 · Balance 161,300 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F8: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.
F2: The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5: The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6: The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F7: Includes 52,350 restricted stock units.
F8: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Zai Lab Ltd
Report date June 25, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 73,000 |
Reported balance
After 2022-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-25 · Grant · Acquired 73,000 · Balance 73,000 F1: Each Restricted Share Unit represents a contingent right to receive one American Depositary Share (ADS), which represents ten Ordinary Shares of the issuer. F2: The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit represents a contingent right to receive one American Depositary Share (ADS), which represents ten Ordinary Shares of the issuer.
F2: The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Elevation Oncology, Inc.
Report date July 23, 2025 · Filed July 24, 2025
Section 16 reporting ended · disclosed 2025-07-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.41 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Disposition to issuer · Disposed 55,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-23 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2035-06-04 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-23 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 23, 2024
Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-01-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-01-23 · Disposition to issuer · Disposed 10,547 · Balance 69,318 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 52,297 · Balance 17,021 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 17,021 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $59.92 · Expires 2032-11-06 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-23 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F6: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
F6: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $58.84 | $0.00 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · derivative · entry 7 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,300 Underlying: Common Stock · 167,300 shares Expires 2035-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F8 · derivative.exercise_date: Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 301 | $204.72 | $61,621.44 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 6 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,559 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F6 · price: The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7 · balance_after: Includes 52,350 restricted stock units. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,199 | $203.91 | $244,484.97 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 5 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,860 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F5 · price: The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,000 | $202.81 | $202,812.70 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 4 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,059 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F4 · price: The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,609 | $201.72 | $324,573.76 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 3 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,059 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F3 · price: The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 2,200 | $200.82 | $441,801.36 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 2 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,668 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. F2 · price: The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 02:00 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 6,000 | $58.84 | $353,040.00 |
DisclosureSEC source: 0001835966-26-000008 · ownership.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 336 | $199.30 | $66,965.88 |
DisclosureSEC source: 0001835966-26-000006 · ownership.xml · nonDerivative · entry 2 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,868 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 52,350 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5 | $194.96 | $974.79 |
DisclosureSEC source: 0001835966-26-000006 · ownership.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,204 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · balance_after: Includes 209 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:30 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 10,100 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001193125-26-018028 · ownership.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Stock · 10,100 shares Expires 2036-01-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. Read SEC document |
| July 23, 2025 Filed Jul 24, 2025 16:40 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-020241 · form4-07242025_040701.xml · derivative · entry 3 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| July 23, 2025 Filed Jul 24, 2025 16:40 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001415889-25-020241 · form4-07242025_040701.xml · derivative · entry 2 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| July 23, 2025 Filed Jul 24, 2025 16:40 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001415889-25-020241 · form4-07242025_040701.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 16:30 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-016272 · form4-06092025_040604.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| April 11, 2025 Filed Apr 15, 2025 20:19 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001415889-25-010692 · form4-04152025_080430.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-11 F1 · derivative.exercise_date: All of the shares subject to the option vest on April 11, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 23:11 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001963 · form4-01232025_110146.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001415889-24-027181 · form4-11192024_091142.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-11-17 F1 · derivative.exercise_date: One-fourth of the shares subject to the option vest on November 18, 2025 and 1/48th of the shares vest monthly thereafter. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 21:23 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 40,400 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001415889-24-020932 · form4-08072024_090845.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,400 Underlying: Common Stock · 40,400 shares Expires 2034-08-04 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on September 5, 2024. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 16:30 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001415889-24-017213 · form4-06172024_080649.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 16:40 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001415889-24-006300 · form4-03042024_090327.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 1/36th of the total shares monthly, beginning on March 29, 2024, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 65,000 | Not disclosed Strike: $59.92 | Not disclosed |
DisclosureSEC source: 0001140361-24-003530 · form4.xml · derivative · entry 4 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2032-11-06 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F6 · price: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 17,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003530 · form4.xml · nonDerivative · entry 3 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 52,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003530 · form4.xml · nonDerivative · entry 2 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,021 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 10,547 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003530 · form4.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,318 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 18:01 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 17,021 | $58.75 | $999,983.75 |
DisclosureSEC source: 0001628280-24-000282 · wk-form4_1704322844.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,318 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 16:19 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 22,297 | $37.00 | $824,989.00 |
DisclosureSEC source: 0001628280-23-028871 · wk-form4_1691698785.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,297 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 18:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantStock Option (Right to buy) · Derivative | 65,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-013305 · marketforms-57442.xml · derivative · entry 2 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-11-06 F2 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 18:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-013305 · marketforms-57442.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date and subject to the reporting persons continuously service to the issuer. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 01:44 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantRestricted Share Units · Derivative | 73,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-024334 · doc4.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: American Depositary Shares · 73,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one American Depositary Share (ADS), which represents ten Ordinary Shares of the issuer. F2 · derivative.exercise_date: The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F2 · derivative.expiration_date: The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionRestricted Share Units · Derivative | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013696 · doc4.xml · derivative · entry 4 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,240 Underlying: American Depositary Shares · 1,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer. F7 · derivative.exercise_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F7 · derivative.expiration_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1 · derivative.underlying: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantRestricted Share Units · Derivative | 16,692 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013696 · doc4.xml · derivative · entry 3 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,692 Underlying: American Depositary Shares · 16,692 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer. F6 · derivative.exercise_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F6 · derivative.expiration_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. F1 · derivative.underlying: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantStock Options (Right to Buy) · Derivative | 87,699 | $0.00 Strike: $45.47 | $0.00 |
DisclosureSEC source: 0000899243-22-013696 · doc4.xml · derivative · entry 2 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,699 Underlying: American Depositary Shares · 87,699 shares Expires 2032-04-01 F3 · shares: The Stock Options are exercisable for ADSs. The number of securities underlying each option and the exercise price therefor are represented in ADSs. Each ADS represents ten Ordinary Shares of the issuer. F4 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 04/01/2023, the first anniversary of the date of grant. F1 · derivative.underlying: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionAmerican Depositary Shares | 1,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013696 · doc4.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. F2 · shares: ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:29 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Tax withholdingOrdinary Shares | 2,075 | $71.23 | $147,802.25 |
DisclosureSEC source: 0001567619-21-021622 · doc1.xml · nonDerivative · entry 1 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,925 F1 · kind: The shares were disposed of through a netting transaction to the issuer to cover taxes due. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:44 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantRestricted Share Units · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014987 · doc4.xml · derivative · entry 2 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Ordinary Shares · 5,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Ordinary Share of the issuer. F3 · derivative.exercise_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. F3 · derivative.expiration_date: The Restricted Share Units vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:44 UTC | Zai Lab Ltd ZLAB · Entity 4271 | GrantStock Options (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $130.96 | $0.00 |
DisclosureSEC source: 0000899243-21-014987 · doc4.xml · derivative · entry 1 Sandler Alan B. · CIK 0001835966 · Head of Global Dev., Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 04/01/2022, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.